Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18469537 | 0.81 | HIF1A (0.44) | HRH3ACHENPC1KDM4EALDH1A1 | |
| SCHEMBL2152345 | 0.81 | HRH4 (0.41) | HRH4HRH3ACHENPC1MEN1 | |
| SCHEMBL12395320 | 0.79 | HRH3 (0.52) | HRH3ACHENPC1KDM4EALDH1A1 | |
| SCHEMBL18469563 | 0.79 | AKR1B1 (0.45) | HRH3ACHENPC1KDM4EALDH1A1 | |
| SCHEMBL12672782 | 0.77 | ACHE (0.36) | HRH3ACHENPC1KDM4EALDH1A1 | |
| SCHEMBL13920381 | 0.77 | ACHE (0.36) | HRH3ACHENPC1KDM4EALDH1A1 | |
| SCHEMBL15724650 | 0.77 | TDP1 (0.56) | HRH4HRH3NPC1MEN1KMT2A | |
| SCHEMBL10696856 | 0.77 | TDP1 (0.56) | HRH4HRH3NPC1MEN1KMT2A | |
| SCHEMBL13652012 | 0.75 | CA2 (0.45) | NPC1AHR | |
| SCHEMBL1701269 | 0.74 | HRH4 (0.49) | HRH4HRH3MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-10588894-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-20190022074-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC | 2019-01-24 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HRH4 2323/4885HRH3 2661/4885ACHE 4843/4885 |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | HRH4 2839/4885HRH3 3512/4885ACHE 4419/4885 |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | HRH4 2352/4885HRH3 3161/4885ACHE 4105/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | HRH4 2839/4885HRH3 3512/4885ACHE 4419/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | HRH4 2839/4885HRH3 3512/4885ACHE 4419/4885 |
| US-10588894-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HRH4 2323/4885HRH3 2661/4885ACHE 4843/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | HRH4 2323/4885HRH3 2661/4885ACHE 4843/4885 |
| US-20190022074-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | HRH4 2323/4885HRH3 2661/4885ACHE 4843/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HRH4 2323/4885HRH3 2661/4885ACHE 4843/4885 |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | HRH4 2323/4885HRH3 2661/4885ACHE 4843/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | HRH4 2839/4885HRH3 3512/4885ACHE 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.